Pro-CME showcases the best-in-class online continuing medical education programs developed for physicians, nurses, and healthcare professionals. We partner with leading medical and healthcare organizations to bring you top CME activities aimed at improving patient care and clinical outcomes. With a variety of multimedia program formats across 29 specialties, Pro-CME provides a destination for clinicians to participate in the latest educational activities for earning credit towards your CME/CE certification.

Spotlight on Gastroenterology

Credits: 0.75 CME
A Pathway to Evidence-Based Management of IBD
Gil Y. Melmed, MD, MS
American Gastroenterological Association

A Pathway to Evidence-Based Management of IBD

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 30, 2018
Expires: October 29, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees).

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Gastroenterology Presentations

1.50 CME
Global Education Group
The Changing Landscape of IBD: Emerging Concepts in Patient Management

The Changing Landscape of IBD: Emerging Concepts in Patient Management

Start

A Multimedia Educational eHealth Source™

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: January 17, 2019
Expires: January 17, 2020
1 hour, 30 mins to complete

Jointly Provided by

Target Audience

This activity is intended for clinical gastroenterologists and specialist NP/PAs involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives

  • Evaluate disease risk and identify individuals who are likely to benefit from biologic or targeted synthetic therapy
  • Tailor management regimens for patients with inflammatory bowel disease (IBD) using a treat-to-target approach that reflects disease severity, treatment goals, therapeutic responses, and patient preferences
  • Partner with patients to provide IBD disease state education, promote shared clinical decision-making, encourage self-management efforts, and personalize long-term care
  • Discuss the cytokine networks underlying IBD pathophysiology, with a focus on newer mechanisms of action
  • Review mechanisms of current and novel non–tumor necrosis factor biologic and targeted synthetic therapies for the treatment of IBD

Activity Description

This activity presents an in-depth review of IBD patient care in moderate to severe disease, including immunopathogenesis of IBD, existing management options, shared decision-making, and investigational targeted therapies, via text and concise video commentaries provided by noted IBD experts

Statement of Educational Need

In the past 2 decades, the introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of the inflammatory bowel diseases (IBDs)—ulcerative colitis and Crohn’s disease. Current biologic therapy with tumor necrosis factor inhibitors and anti-integrins has improved the treatment of IBD flares and maintenance of clinical remission. These agents are, however, limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the pathogenesis and treatment of IBD are complex and variable, there is a need to better understand the underlying pathogenic mechanisms and develop drug therapies to target these mechanisms.1

Geared to the needs of gastroenterologists, this IBD eHealth program includes an update on patient assessment and treat-to-target goals, as well as a review of best practices in shared decision-making in treatment decisions for induction and maintenance of remission. In addition, the immunopathogenesis of IBD is discussed in the context of current and emerging targeted therapies for moderate to severe disease.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.

Agenda

  • Chapter 1: Assessment Strategies and Treatment Goals in IBD
  • Chapter 2: Best Practices in Tailoring Treatment of Moderate and Severe IBD
  • Chapter 3: Evolving Concepts in IBD Pathophysiology
  • Chapter 4: Targeted Mechanism-Based Therapies for IBD on the Horizon

Faculty

Raymond K. Cross, MD, MS
Professor of Medicine
Director, Inflammatory Bowel Disease Program
University of Maryland School of Medicine
Co-Director, Digestive Health Center
University of Maryland Medical Center
Baltimore, MD


Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA


Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Raymond K. Cross, MD, MS
  • Consultant/Independent Contractor: AbbVie Inc, Janssen, LabCorp, Pfizer, UCB
  • Grant/Research Support: AbbVie Inc

Gary R. Lichtenstein, MD
  • Consultant: AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Luitpold Pharmaceuticals, Inc., Merck & Co., Pfizer Inc., Prometheus Laboratories Inc., Romark, L.C., Salix Pharmaceuticals, Inc., Shire Plc, Takeda Pharmaceuticals North America, Inc., UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Grant/Research Support: Celgene Corporation, Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Plc, UCB, Inc., Valeant Pharmaceuticals International, Inc.
  • Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastroenterology and Hepatology (Gastro-Hep Communications, Inc.), Luitpold Pharmaceuticals, Inc., McMahon Publishing, Merck & Co., Romark, L.C., Springer Science+Business Media, UpToDate®
  • Other/Royalty: Eli Lilly and Company (Data and Safety Monitoring Board), Janssen Pharmaceuticals, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), Pfizer Inc. (Funding for IBD Fellow Education to the University of Pennsylvania), SLACK, Incorporated (Book Royalty), Takeda Pharmaceuticals North America, Inc. (Funding for IBD Fellow Education to the University of Pennsylvania)

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity: Lindsay Borvansky, Andrea Funk, Liddy Knight, Kayla Messer, Jim Kappler, PhD, Julia Muino.

Designation of Credit

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the post-test and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
American Gastroenterological Association
Optimizing Management in IBD: Challenging Cases

Optimizing Management in IBD: Challenging Cases

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 26, 2018
Expires: December 25, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS (Chair)
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA


Adam S. Cheifetz, MD
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA


Gary R. Lichtenstein, MD, FACP, FACG, AGAF
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees); Pfizer (Research).
  • Adam S. Cheifetz, MD, has affiliations with AbbVie, Arena, Ferring, Janssen, Pfizer, Samsung, Takeda (Consulting Fees); Miraca (Grant/Research Support).
  • Gary R. Lichtenstein, MD, FACP, FACG, AGAF, has affiliations with Abbott Corporation/AbbVie, Celgene, CellCeutrix, Ferring, Gilead, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals, Shire, Takeda, UCB (Consulting Fees); Celgene, Janssen Orthobiotech, Salix Pharmaceuticals, Shire, UCB (Research); Luitpold/American Regent, Merck, Romark (Other Financial Benefit).  

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME
The Postgraduate Institute for Medicine
IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

IBD In Clinical Practice: Malnutrition Update For Healthcare Providers 2018

Start

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: March 29, 2018
Expires: March 29, 2019
1 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists and gastroenterology nurse practitioners (NPs) and physician assistants (PAs) who manage patients with IBD.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Summarize the clinical significance of malnutrition and related complications
  • Identify IBD patients who are at risk for malnutrition by using the Malnutrition Universal Screening Tool (MUST)
  • Describe screening, assessment, and intervention/monitoring for malnutrition in IBD patients as outlined by the CCFA IBD Nutrition Care Pathway
  • Engage IBD patients who are at risk or have malnutrition in their healthcare by implementing effective shared decision making strategies

Faculty

Caroline Hwang, MD
Caroline Hwang, MD
Assistant Professor of Clinical Medicine
Medical Director, Inflammatory Bowel Disease Center
Keck/University of Southern California School of Medicine
Los Angeles, CA


Kelly Issokson, MS, RD, CNSC
Kelly Issokson, MS, RD, CNSC
Clinical Dietitian
Cedars-Sinai Medical Center
Los Angeles, CA


Gil Y. Melmed, MD, MS
Gil Y. Melmed, MD, MS
Director of Clinical Inflammatory Bowel Disease (IBD) 
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen University of California, Los Angeles (UCLA) School of Medicine
Los Angeles, CA


Aline Charabaty, MD (Reviewer)
Aline Charabaty, MD (Reviewer)
Associate Professor of Medicine
Director, IBD Center
Medstar Georgetown University Hospital
Washington, DC


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Caroline Hwang, MD, has affiliations with UCB (Consulting Fees); Janssen, Nestlé Health Science (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); AbbVie, Celgene, Eli-Lilly (Contracted Research).
  • Kelly Issokson, MS, RD, CNSC, has no affiliations with commercial interests to disclose.
  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Celgene, Janssen, Medtronic, Pfizer, Takeda, UCB (Consulting fees).
  • Aline Charabaty, MD, has affiliations with AbbVie (Consulting Fees); AbbVie, Janssen, Takeda (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents); Janssen (Contracted Research).

Crohn’s & Colitis Foundation of America

  • Sudha Sarode, MSPH, has no affiliations with commercial interests to disclose.

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Faith Reidenbach, CHCP, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page.
Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn's & Colitis Foundation, and RMEI Medical Education, LLC. This activity is supported by an independent medical educational grant from Nestlé Health Science.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware / Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.75 CME
American Gastroenterological Association
A Pathway to Evidence-Based Management of IBD

A Pathway to Evidence-Based Management of IBD

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: October 30, 2018
Expires: October 29, 2019
0.75 hour to complete

Accredited By

The American Gastroenterological Association (AGA) Institute

Target Audience

Gastroenterologists and gastroenterology NPs and PAs

Learning Objectives

  • Differentiate between current, novel, and future IBD therapies based on their efficacy and safety data
  • Devise an individualized and adaptable treatment plan for patients with IBD to maximize remission, avoid relapse, and minimize toxicity
  • Assess disease progression and utilize drug monitoring strategies to optimize treatment of patients with IBD
  • Employ a strong patient-provider collaborative approach to managing patients with IBD that includes patient education, engagement, and shared decision making

Faculty

Gil Y. Melmed, MD, MS
Co-Director, Clinical Inflammatory Bowel Disease
Division of Gastroenterology/Department of Medicine
Cedars-Sinai Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure of Conflicts of Interest

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Gil Y. Melmed, MD, MS, has affiliations with AbbVie, Janssen, Medtronic, Pfizer, Samsung Bioepis, Takeda (Consulting Fees).

RMEI Medical Education, LLC

  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
  • Sharon Powell, has no affiliations with commercial interests to disclose.

AGA Institute

  • Monique Dyson, has no affiliations with commercial interests to disclose.
  • Sandra Amos, has no affiliations with commercial interests to disclose.

Physician Continuing Medical Education

The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. After the successful completion of A Pathway to Evidence-Based Management of IBD and Optimizing Management in IBD: Challenging Cases, learners will receive an AGA-branded certificate recognizing their mastery of IBD management.



COMPLETE THE EVALUATION FORM AND GET A CHANCE TO WIN A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.
 
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.


Statement of Commercial Support

This activity is supported by independent educational grants from Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Salix Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.25 CME / CNE
Vindico
Improving Colorectal Cancer Screening and Prevention: Advances in Polyp Detection and Resection

Improving Colorectal Cancer Screening and Prevention: Advances in Polyp Detection and Resection

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: October 1, 2018
Expires: October 1, 2019
75 minutes to complete

Provider Statement

This continuing education activity is provided by

Support Statement

This continuing educational activity is supported by an educational grant from Aries Pharmaceuticals, Inc.

Activity Chair

(1) Latest Advances to Improve Polyp Resection
(2) Case Presentations

Douglas K. Rex, MD
Distinguished Professor of Medicine
Indiana University
Indianapolis, IN
Disclosures:
Consulting Fee: Aries Pharmaceuticals, Inc, Boston Scientific, Braintree, Cosmo Pharmaceuticals, Olympus
Contracted Research: Boston Scientific, Braintree, EndoAid Ltd, Medivators, Medtronic, Olympus, PAION, Sebela

Faculty

Increasing Adenoma Detection Rates: Improving Colorectal Cancer Outcomes
David A. Johnson, MD, MACG, FASGE, FACP
Professor of Medicine
Chief of Gastroenterology
Eastern Virginia Medical School
Norfolk, VA
Disclosures:
Consulting Fee: Aries Pharmaceuticals, Inc, CRH Medical, Pfizer, WebMD/Medscape


Tools and Devices to Improve Adenoma Detection Rates
Prateek Sharma, MD
Professor of Medicine
University of Kansas School of Medicine
Kansas City, MO
Disclosure: No relevant financial relationships to disclose.

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Nurse Planners

Barbara A. Niedz, PhD, RN, CPHQ
Disclosure: No relevant financial relationships to disclose.

Kelli C. Kneisel, FNP
Disclosure: No relevant financial relationships to disclose.

Medical Writer

Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

This enduring material is approved for 1 year from the date of original release, October 1, 2018 to October 1, 2019.

How to Participate in This Activity and Obtain CME/CNE Credit

To participate in this CME/CNE activity, you must answer the pre-activity questions, read the objectives and articles, and complete the post-activity questions and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the post-activity questions correctly. Upon receipt of the completed materials, if a satisfactory score on the post-activity is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ or Learner-Paced Contact Hours certificate immediately.

Overview

Colorectal cancer (CRC) is the third most common type of cancer worldwide and the second deadliest form of cancer in the United States. Studies on CRC screening show that for every 1% increase in a physician’s adenoma detection rate (ADR), the risk of colon cancer developing in their patients over the next year decreases by 3%. Thus, if physicians are proficient at finding and removing precancerous polyps during colonoscopy, cancer is less likely to develop. However, estimates suggest that up to 25% of adenomas are missed with current colonoscopy technologies, primarily due to poor visualization in folds and other difficult-to-detect areas. Modifiable factors to improve detection rates include colonoscopy team behaviors during procedures, endoscope design, and targeted education. Technological advances and strategies to improve visualization, as well as field of view, have improved detection rates in recent years, and more strategies are in development. In addition, when an adenoma is detected, the use of injectable solutions, such as artificial tears, hetastarch, or viscous agents with medium-chain triglycerides and methylene blue, may provide long-lasting submucosal lift and cushion to reduce the risk of perforation during removal. This educational activity will focus on strategies to improve polyp identification and reduce endoscopic resection risks.

Target Audience

This program is designed for gastroenterologists, nurses, and other health care professionals involved in the screening of patients for colorectal cancer (CRC).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:
Physician Learning Objectives:

  • Examine trends in the incidence rates of CRC as well as the importance of appropriate screening and early detection.
  • Utilize appropriate strategies and devices to improve adenoma detection rates (ADR).
  • Identify polyps that may be better suited for endoscopic versus surgical removal.
  • Apply the latest technical advances to the resection of gastrointestinal polyps for cancer prevention.

Nurse Learning Objectives:

  • Examine trends in the incidence rates of CRC as well as the importance of appropriate screening and early detection.
  • Utilize appropriate strategies and devices to improve ADR.
  • Review the latest technical advances for the resection of gastrointestinal polyps for cancer prevention.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Vindico
Therapeutic Drug Monitoring in Crohn’s Disease: Personalized Approaches for Treatment Optimization

Therapeutic Drug Monitoring in Crohn’s Disease: Personalized Approaches for Treatment Optimization

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credits
Released: August 31, 2018
Expires: August 31, 2019
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with Crohn's disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the mechanisms behind primary and secondary non-response to biologic agents in the treatment of Crohn’s disease.
  • Utilize strategies that mitigate the loss of response to a biologic agent in Crohn’s disease.
  • Incorporate new guidelines and best practices regarding the use of therapeutic drug monitoring in the management of Crohn’s disease.
  • Apply new evidence regarding the safety and efficacy of biologic agents used in the long-term management of Crohn’s disease.

Activity Description

Despite the proven therapeutic efficacy of anti-tumor necrosis factor (TNF) agents, treatment failures due to primary nonresponse or secondary loss of response (LOR) can occur in patients with Crohn’s disease. Approximately 10% to 20% of patients with inflammatory bowel disease have been reported to be unresponsive to induction treatment with anti-TNF agents. A significant portion of those patients who initially respond to anti-TNF treatment lose response over time, with an annual increased risk of 13% to 24%. Several distinct mechanisms for secondary LOR have been suggested, including the formation of antidrug antibodies. In clinical practice, therapeutic drug monitoring (TDM) has been shown to be clinically useful, cost-effective, and associated with improved clinical and endoscopic outcomes. The use of TDM in patients with Crohn’s disease provides a personalized approach to optimize treatment, with new guidelines for its use now available. In addition, the measurement of drug concentrations and antidrug antibodies can be used to improve treatment outcomes. This case-based activity is intended to help clinicians integrate scientific advances into real-world practice settings, assess the causes of LOR, incorporate new guidelines into practice, and effectively utilize TDM for patients receiving biologic agents.

Agenda

  • Decisions, Decisions…Primary and Secondary Loss of Response to Biologics in Crohn’s Disease
  • Therapeutic Drug Monitoring in the Management of Crohn’s Disease
  • Case Presentation – Loss of Response, TDM, and Dose Optimization

Faculty

Bruce E. Sands, MD, MS (Activity Chair)
Chief, Dr. Henry D. Janowitz Division of Gastroenterology 
Dr. Burrill B. Crohn Professor of Medicine 
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System 
New York, NY

Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Capella Bioscience, Celgene, EnGene, Ferring, Gilead, Janssen, Lilly, Lyndra, MedImmune, Oppilan, Otsuka, Palatin Technologies, Pfizer, Rheos Medicines, Seres Therapeutics, Takeda, Target PharmaSolutions, Theravance, TiGenix, Vivelix
Contracted Research: Celgene, Takeda


Edward V. Loftus Jr., MD
Professor of Medicine 
Consultant, Division of Gastroenterology and Chair, Inflammatory Bowel Disease Interest Group 
Mayo Clinic 
Rochester, MN

Consulting Fee: AbbVie, Amgen, Celgene, Celltrion Healthcare, Eli Lilly, Janssen, Napo Pharma, Pfizer, Takeda, UCB
Contracted Research: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Pfizer, MedImmune, Receptos, Robarts Clinical Trials, Seres Therapeutics, Takeda, UCB


Marla Dubinsky, MD
Chief, Pediatric Gastroenterology and Hepatology
Co-Director, the Susan and Leonard Feinstein IBD Clinical Center
Icahn School of Medicine at Mount Sinai
New York, NY

Consulting Fee: AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen, Pfizer, Prometheus, Salix, Shire, Takeda, UCB


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.  Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from UCB, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
The University of Pittsburgh School of Medicine
IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

IBD in Clinical Practice: Diagnosis and Medical Treatment - 2018

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
1 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases
  • Apply principles of therapeutic management according to clinical symptoms, duration, and severity of disease

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .10 continuing education units (CEUs), which are equal to 1.0 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 65% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from AbbVie Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.50 CME
The University of Pittsburgh School of Medicine
IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

IBD in Clinical Practice: Long-term Disease Management and Surgery - 2018

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: May 3, 2018
Expires: May 2, 2019
0.5 hour to complete

Target Audience

Physicians, gastroenterologists, nurse practitioners, and physician assistants

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Decide which medical treatment to use in acute IBD flares and for long-term disease management
  • Identify IBD characteristics for which surgery is indicated

Jointly Provided By

This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation.

Faculty

Miguel Regueiro, MD
Miguel Regueiro, MD
Chair, Department of Gastroenterology and Hepatology
Professor, Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Dr. Regueiro has affiliations (Consultant) with AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres, Takeda, UCB; (Research) with AbbVie, Janssen, Takeda; (Unrestricted Educational Grants) with AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB.


Hans Herfarth, MD, PhD
Hans Herfarth, MD, PhD
Professor of Medicine
University of North Carolina
Chapel Hill, NC

Dr. Herfarth has affiliations (Consultant) with Allergan, Boehringer, Celltrion, Lycera, Merck, Pfizer, Samsung, Seres.


Conflict of Interest Policy/Disclosure Statement

Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing healthcare goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this educational activity have relevant financial relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other healthcare professionals are awarded .05 continuing education units (CEUs), which are equal to 0.5 contact hour. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit™.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 75% or higher on the post-test to receive credit for this activity. You will have 3 attempts to take the post-test.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by educational grants from Salix Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

1.00 CME
Vindico
Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Improving the Continuum of Care in Patients with Inflammatory Bowel Disease: A Patient Simulation Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: February 15, 2018
Expires: February 14, 2019
1 hour to complete

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Simulation-services provided by Syandus

Support Statement

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Activity Chair

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA

Disclosure:
Royalty: SLACK Incorporated;
Consulting Fees: Abbott/AbbVie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer, Prometheus, Romark, Salix, Santarus, Shire, Takeda, UCB;
Contracted Research: Ferring, Prometheus, Salix, Santarus, Shire, UCB;
Research Grant (paid to institution): Janssen Orthobiotech;
Author Honoraria: McMahon Publishing, Up to Date;
Editor Honoraria: Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media.



Faculty

Meenakshi Bewtra, MD, PhD, MPH
Assistant Professor of Medicine and Epidemiology
Center for Clinical Epidemiology and Biostatistics
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosure:
Contracted Research: GlaxoSmithKline, Takeda.



Nabeel Khan, MD
Assistant Professor of Clinical Medicine
Raymond and Ruth Perelman School of Medicine
University of Pennsylvania
Director of Gastroenterology
Philadelphia VA Medical Center
Philadelphia, PA

No relevant financial relationships to disclose.


Reviewer

Ronald Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 15, 2018 to February 14, 2019.

How To Participate in this Activity and Obtain CME Credit

  • Read the target audience, learning objectives, and faculty disclosures.
  • Launch the simulation from the link provided on GastroCE.com on a PC, Mac, tablet, or plus-size phone.
  • Complete the pretest and launch the first simulation scenario. Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all scenario objectives and assessment components are complete. You can exit the simulation and it will save your progress so that you can return to finish at a later time.
  • As you successfully complete more scenarios (2 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.00 credits). Click or tap "Credit" to determine your CE credit status and receive credit. Upon successful completion of the evaluation, you will receive a certificate of credit immediately via the browser.

Overview

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Improvement in the care of patients with IBD is needed, as evidenced by a recent study of insurance claims that showed approximately 80% of 32,883 patients with IBD received suboptimal therapy. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies.

To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD to avoid disease flares, prevent structural damage and disability, as well as restore quality of life. In this virtual IBD patient management simulator, an authentic in-office setting with patient interaction will be presented. This simulation will allow authentic practice in the management of a patient with IBD, including determining the appropriate therapy for IBD based on the type and severity.

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the treatment of patients with IBD.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Analyze endoscopic and histologic findings that are characteristic of specific types of inflammatory bowel disease.
  • Apply the safety and efficacy of conventional and new treatments when determining the appropriate therapy for inflammatory bowel disease, based upon type and severity.
  • Incorporate therapeutic drug monitoring, stool markers, and the assessment of mucosal healing in monitoring inflammatory bowel disease as well as in response to treatment, to better predict exacerbations.

Copyright Statement

This CME simulation activity is licensed to Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Copyright © 2018 Syandus Inc and Vindico Medical Education. All rights reserved. No part of this simulation activity may be reproduced without written permission from Vindico Medical Education and Syandus Inc. The material presented in this Vindico Medical Education continuing medical education activity does not necessarily reflect the views and opinions of Vindico Medical Education or Syandus Inc. Neither Vindico Medical Education, Synadus Inc, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com